Theravance Biopharma Q4 2023 GAAP EPS $(0.17) Misses $(0.15) Estimate, Sales $17.57M Miss $17.68M Estimate
Theravance Biopharma Q4 2023 GAAP EPS $(0.17) Misses $(0.15) Estimate, Sales $17.57M Miss $17.68M Estimate
Theravance Biopharma 2023年第四季度GAAP每股收益（0.17）未达到预期（0.15）美元，销售额为1757万美元，未达到1768万美元的预期
Theravance Biopharma (NASDAQ:TBPH) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.15) by 13.33 percent. The company reported quarterly sales of $17.57 million which missed the analyst consensus estimate of $17.68 million by 0.67 percent. This is a 19.91 percent increase over sales of $14.65 million the same period last year.
Theravance Biopharma（纳斯达克股票代码：TBPH）公布的季度亏损为每股0.17美元，比分析师普遍预期的0.15美元（0.15美元）低13.33％。该公司公布的季度销售额为1757万美元，比分析师普遍预期的1768万美元低0.67％。这比去年同期的1465万美元销售额增长了19.91％。